Selective ALK inhibitor shows NSCLC promise

Preliminary trial results suggest that a novel, highly selective ALK inhibitor may be effective for the treatment of advanced non-small-cell lung cancer in Japanese patients with the ALK rearrangement.

via Med Wire News